Sharayu Kachare’s Post

Sharayu Kachare and I are excited to highlight our latest insights into the innovative advancements in psoriasis treatment!" Did you know that new treatments for psoriasis are changing the way we manage this challenging skin condition? Psoriasis affects millions of people worldwide, often leading to discomfort and a reduced quality of life. As a healthcare professional, staying updated on the latest treatment options is crucial to improving patient outcomes. In our latest clinical review, we explore the advancements in both topical and systemic treatments for psoriasis. From new topical formulations to cutting-edge biologics and JAK inhibitors, this article dives into the most recent innovations, their mechanisms, and their clinical benefits. #Psoriasis #Dermatology #Healthcare #ClinicalReview #InnovativeTreatments

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #AtopicEczemaDay

🌟Publication Alert! 🌟 We are excited to announce our latest research article titled "Association Between Medication Use and Bullous Pemphigoid: A Ten-Year Systematic Review." Research paper by Ronauli Agnes Marpaung, Fina Retnawati Sihombing This comprehensive study delves into the intricate relationship between various medications and their impact on bullous pemphigoid, a rare but significant skin condition. 🔑 Key Highlights: Focus: Examines the association between specific drugs and the incidence of bullous pemphigoid (BP). Methodology: A rigorous ten-year systematic review, ensuring robust and reliable findings. Relevance: Provides critical insights that can aid healthcare professionals in understanding medication risks and patient management strategies. This research contributes valuable knowledge to the field of dermatology and pharmacology, paving the way for safer medication practices. 📝 Read the full article in our journal and stay informed on the latest advancements in medical science! 👉Link to the article: https://lnkd.in/gABg58aT #MedicalResearch #Pharmacology #Dermatology #BullousPemphigoid #SystematicReview #Healthcare

📊 One of the most rewarding aspects of being involved in new drug discovery is the opportunity to learn, even when outcomes don’t align with initial expectations. Our latest publication highlights a two-part trial of BI 730357, a RORγt inhibitor, in plaque #psoriasis. Congrats to my co-authors Kim Papp, Ulrich Mrowietz, Mary Flack, Howard Sofen, Werner Kadus, Kristin Drda, Hui Gu, Harald Vangerow, and Julia Korell 👏 https://lnkd.in/ggZJUR9s In summary, the study demonstrated moderate efficacy at doses up to 200 mg, with 30% of patients achieving PASI 75 and 27.5% reaching clear/almost clear skin (sPGA) at 12 weeks. The treatment was well-tolerated, with drug-related adverse events in ≤18.5% of patients during the long-term extension. The journey of studying all possibilities advances our understanding—and every step brings us closer to improved care for patients!! #Dermatology #DrugDiscovery #PsoriasisResearch #PsoriasisTherapeutics

Galderma has reported that the randomised Phase III OLYMPIA 1 trial, which evaluated the nemolizumab monotherapy in adult subjects with moderate-to-severe prurigo nodularis (PN), has achieved both primary and all key secondary goals. GALDERMA R&D global head Baldo Scassellati Sforzolini said: “These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent US Food and Drug Administration approval for the treatment of adults with PN" Click here for the full article - https://lnkd.in/dCT3sRJx #clinicaltrials #dermatology

On this World Atopic Eczema Day, LEO Pharma shines a spotlight on atopic dermatitis (AD) - the most common form of eczema that affects millions of people across the globe. This chronic inflammatory skin condition not only causes physical discomfort with symptoms such as itch and pain, but also impacts the quality of life for patients, their families and caregivers. With AD often persisting into and sometimes beginning in adulthood, the condition results in a lifetime patient burden that is one of the largest among diseases worldwide. At LEO Pharma, we are driven to innovate to address such patient needs and strive to make a fundamental difference for those living with skin conditions. #LEOPharma #DermatologyBeyondTheSkin #WorldAtopicEczemaDay #AtopicDermatitis

The latest #psoriasis slide decks are now available on the #IMIDForum! Explore new insights and data to enhance your practice with the top research in #dermatology: [LINK] This month’s Literature Highlights are now available on the Immune-Mediated Inflammatory Disease Forum! November’s single slide summary includes a study by Huang, et al., where they aimed to identify predictors and construct a predictive model for time to relapse following withdrawal from biologics. Find out more about this publication, and more about #psoriasis on the IMID Forum today. 🔗https://ow.ly/z06850UhCMV

The emerging landscape of targeted therapies, particularly biologics and small molecule agents, offers new hope by providing more effective and tailored treatment options. However, the integration of personalized treatment strategies, and patient-centered care remains crucial for optimizing outcomes and enhancing the quality of life for psoriasis patients. This podcast will discuss these key issues and explore the potential of innovative therapies in improving patient outcomes. Follow the link in our bio for FREE AMA, ABS, ANCC or ACPE credit! #psoriasis #dermatology #practicepointcme #freecme

Check out the NACE Webcast: Atopic Dermatitis: Evaluation and Targeted Management. Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that commonly presents in childhood. It is characterized primarily by scaly, pruritic, erythematous lesions located on flexural surfaces. The itch that accompanies AD has a significant impact on patients’ quality of life, with the most prominent impact being on sleep quality. Fortunately, a new understanding of its underlying pathophysiology has brought about a variety of effective treatment options for patients suffering from AD, from topical agents to biologics and oral Janus kinase (JAK) inhibitors. In this webcast, Mona Shahriari, MD, FAAD, will share her valuable insights on differential diagnosis, treatment goals, and individualizing treatment plans. Click here to start the course: https://bit.ly/3WdObsm #NACE #Dermatology #Webcast